Passive Immunity: How Monoclonal Antibodies Protect Without Training the Immune System

Passive immunity is protection you receive ready-made. Instead of teaching the immune system to build its own antibodies, a clinician administers antibodies manufactured in advance, and they begin neutralizing a pathogen within hours. Monoclonal antibodies such as palivizumab and nirsevimab work exactly this way against respiratory syncytial virus (RSV): they bind the virus directly, block it from entering cells, and protect the recipient immediately. The trade-off is that this protection fades as the injected antibodies clear from the body, and it leaves behind no immune memory, which is the opposite of what a vaccine does.

What "passive" means at the molecular level

A review of passive immunization in the primary literature describes the approach plainly: preformed antibodies are given to a susceptible host to provide immediate but temporary protection, without triggering the host to mount its own response. The workhorse molecule is immunoglobulin G (IgG), a Y-shaped protein of about 150 kilodaltons that circulates in serum and binds a defined target.

Because the recipient's own B cells and T cells are never engaged, there is no learning curve. Protection is present the moment the antibody reaches the bloodstream. That same fact explains the limitation. The antibody is a consumable. As the liver and other clearance pathways remove it, the shield thins and eventually disappears. Nothing is left in reserve to respond faster the next time the pathogen appears.

Monoclonal versus polyclonal

Not all antibody preparations are alike. Polyclonal products contain a mixture of antibodies from many B cell clones, each recognizing a slightly different piece of a target. Monoclonal antibodies come from a single clone and therefore bind one precise site with uniform behavior. That precision is what makes a modern monoclonal predictable enough to dose like a drug, and it is why the RSV products discussed below target one specific structure on the virus.

How this differs from a vaccine

A vaccine does the opposite of a passive antibody injection. It presents an antigen and lets the recipient's immune system generate its own antibodies and memory cells over a period of weeks. The payoff is durability: after the response matures, memory cells can regenerate protection quickly for months or years. The cost is time. Active immunity is useless in the first days after exposure because the response has not yet formed.

This distinction matters most when the vulnerable window is short and early. A newborn entering their first RSV season cannot wait weeks to build immunity, and their own immune machinery is still immature. A preformed antibody sidesteps both problems by supplying finished protection on day one. A useful nuance sits alongside this: maternal RSV vaccination is active immunization of the mother, but the antibodies she makes cross the placenta and protect the infant passively. The infant, in other words, borrows immunity it did not build.

Two RSV monoclonals, two design philosophies

Palivizumab was the first antiviral monoclonal antibody in wide clinical use. It binds antigenic site II on the RSV fusion (F) protein and prevents the virus from entering host cells. Its weakness is pharmacokinetic: with a half-life of roughly 18 to 21 days, it must be re-dosed by intramuscular injection every month across the RSV season to keep antibody levels high enough to matter. A review of its trial record traces its approval to the pivotal IMpact-RSV study, which showed about a 55 percent relative reduction in RSV hospitalization among high-risk infants.

Nirsevimab reflects a later generation of protein engineering. A small set of changes to the antibody's tail (the YTE modification) strengthens its binding to the neonatal Fc receptor, which recycles IgG and slows its clearance. The result is a half-life near 71 days, long enough that a single injection covers an entire RSV season, and neutralizing antibody levels roughly ten times higher than monthly palivizumab produces, as summarized in a recent review of RSV monoclonals. The U.S. Food and Drug Administration approved nirsevimab in July 2023.

The efficacy signal is strong and consistent across trials. Pooled trial data cited by the CDC Advisory Committee on Immunization Practices put efficacy at 79.0 percent against medically attended RSV lower respiratory tract infection, 80.6 percent against RSV hospitalization, and 90.0 percent against admission to intensive care. On that basis, ACIP recommended one dose for all infants younger than eight months born during or entering their first RSV season.

How prevention benefit is actually measured

Percentages like "55 percent" and "79 percent" are relative risk reductions. They describe how much a monoclonal cuts the chance of an outcome, but they say nothing about how common that outcome was to begin with. Two other numbers do that work.

Absolute risk reduction is the plain difference in event rates between treated and untreated groups. Its inverse is the number needed to treat, or in a prevention context the number needed to immunize: how many people you must protect to prevent one event. The palivizumab review reports the underlying rates directly. Among the premature infants studied, RSV hospitalization fell from 8.1 percent on placebo to 1.8 percent with palivizumab, an absolute reduction of about six percentage points. Dividing one by that difference gives a number needed to immunize of roughly sixteen, meaning about sixteen infants had to receive the antibody to keep one out of the hospital.

That figure is not a fixed property of the drug. It depends heavily on baseline risk. The same relative reduction yields a smaller number needed to immunize (more benefit per dose) in a high-risk population and a larger one in a low-risk population. This is why prevention decisions weigh who is being protected, since a percentage alone cannot tell you how many doses stand behind each prevented hospitalization. A responsible reading of any prevention claim asks for the absolute numbers behind the headline percentage.

This article is educational and not medical advice; decisions about RSV prevention for a specific child belong with a qualified clinician.

The bottom line

Passive immunity trades durability for speed. Monoclonal antibodies against RSV give an infant immediate, well-characterized protection during the exact weeks they are most vulnerable, then wash out, which is why they are re-dosed each season rather than remembered like a vaccine. Judging their value means reading past the relative percentage to the absolute risk reduction and the number needed to immunize, because those numbers, anchored in the treated population's baseline risk, are what tell you how much real-world protection a dose buys.